The company’s shift centers on its Augusta platform, which utilizes AI and large-scale toxicity databases to identify neurotoxic threats. This technology now forms the core of a multi-year defense collaboration through BioSymetrics, aligning with mandates in the 2027 Defense Authorization Bill. To bolster this, the firm established the Pathfinder Consortium, a research alliance featuring Harvard University, Brigham and Women’s Hospital, and Purdue University. Beyond defense, Lunai continues to develop its precision neurology pipeline for epilepsy, Parkinson’s, and Alzheimer’s, supported by NIH grants.

While scaling its technical operations, leadership is focused on stock market volatility. In May 2026, the company filed a lawsuit in the U.S. District Court for the District of Delaware, alleging naked short selling. The filing cites 29.6 million shares marked as failing-to-deliver, representing 81.6% of outstanding equity. A judge has granted expedited discovery, allowing the company to subpoena trading records to identify parties behind the volume. Weinstein asserts that this litigation is a protective measure intended to restore suppressed shareholder value and force transparency in market practices.